31 July 2020 | News
Collaboration aims to enable discovery of first-in-class therapeutic candidates
Image credit- shutterstock.com
China based Viva Biotech Holdings and Schrödinger, Inc. in the US have announced a strategic collaboration to expand the reach of structure-based drug discovery by generating de novo crystal structures of high-value targets.
Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.
Viva Biotech will deploy X-ray crystallography designed to structurally enable these targets by generating high-resolution structures with bound ligands.
Schrödinger will then leverage its advanced computational platform at scale to explore large portions of chemical space with the goal of designing novel therapeutic candidates for such targets.